Abstract

Cathelicidin-BF-30 (BF-30), a water-soluble peptide isolated from the snake venom of Bungarus fasciatus containing 30 amino acid residues, was incorporated in poly(D,L-lactide-co-glycolide) (PLGA) 75∶25 microspheres (MS) prepared by a water in oil in water W/O/W emulsification solvent extraction method. The aim of this work was to investigate the stability of BF-30 after encapsulation. D-trehalose was used as an excipient to stabilize the peptide. The MS obtained were mostly under 2 µm in size and the encapsulation efficiency was 88.50±1.29%. The secondary structure of the peptide released in vitro was determined to be nearly the same as the native peptide using Circular Dichroism (CD). The ability of BF-30 to inhibit the growth of Escherichia coli was also maintained. The cellular relative growth and hemolysis rates were 92.16±3.55% and 3.52±0.45% respectively.

Highlights

  • BF-30 is a 30-residue peptide isolated from the venom of the snake Bungarus fasciatus, which exhibits broad antimicrobial activity against bacteria and fungi

  • Morphology characterization Microspheres prepared by the W/O/W emulsion/solvent evaporation/extraction method with a high yield of 76.6468.07% according to the equation (3)

  • To test the biological effect of the released peptide, we investigated the activity of release medium on the 1st, 10th, 11th,and 12th days against Escherichia coli, which is sensitive to BF30 [1,2]

Read more

Summary

Introduction

BF-30 is a 30-residue peptide isolated from the venom of the snake Bungarus fasciatus, which exhibits broad antimicrobial activity against bacteria and fungi. The peptide has a short half-life in serum [3], which may be caused by proteases present in serum [4]. Attempts have been made to increase the stability of BF-30 by chemical modification of the peptide through pegylation to extend the half-life [5,6]. Pegylation is a chemical modification method for increasing the stability of peptide by conjugating PEG to peptide or protein, the process may have an effect on the therapeutic effect of the peptide [3]. An alternative route to improve stability is to formulate the chemically intact peptide in a suitable carrier vehicle [3]

Objectives
Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.